This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed C
Age, gender, average time between the chest radiograph and the CT in days, and projection type are displayed for the diseased and normal cases. n = number. Patient demographics.